# Access to technologies within the network

Industrial Partners can get access to the methodologies and state-ofthe-art equipment of competent academic units. TEDD team provides individual advice on how to find the most competent partner for a project, considering its concept and demands.

### Expanded market and advertisement platform

During TEDD meetings, priority is given to Partners to present their products to the 3D cell culture and MPS community. Each partner's logo is displayed on the TEDD website to increase awareness of their competences, products and services.

#### Access to selected scientific information free of charge

Partners receive password-protected access to scientific information, selected publications, and presentations from conferences in the 3D cell culture field.

## Exhibition opportunities

Partners have exclusive admission to exhibit during one- or two-day TEDD Annual Meetings at no or low costs.



# **General Information**

#### Lead

Dr Markus Rimann, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, Wädenswil

# **Project Management**

Dr Kasia Kopanska, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, Wädenswil

# **Steering Committee**

Dr Markus Rimann, ZHAW, Wädenswil Prof Katharina Maniura, Empa, St. Gallen Dr Jens Kelm, PreComb Therapeutics AG, Hombrechtikon Dr Oliver Peter, Idorsia Pharmaceuticals Ltd., Allschwil Prof Giuseppe Perale, IBI-S.A., Mezzovico-Vira

# **Advisory Board**

Prof Ursula Graf-Hausner, graf 3dcellculture, Winterthur Dr Markus Ehrat, EK Biosciences GmbH, Magden Dr Uwe Marx, TU Berlin, Germany Prof Thomas Singer, F. Hoffmann-La Roche, Basel Prof Marcus Textor, ETH Zürich, Zürich Marc Thurner, mimiX Biotherapeutics Ltd., Wavre





# Contact

ZHAW Zurich University of Applied Sciences Life Sciences und Facility Management PO Box 8820 Wädenswil/Schweiz info.tedd@zhaw.ch

www.zhaw.ch/icbt/tedd





# **Competence Centre TEDD**

Tissue Engineering for Drug
Development and Substance Testing

Institute of Chemistry and Biotechnology, Campus Reidbach, Switzerland www.zhaw.ch/icbt/tedd



# **Vision**

TEDD (Tissue Engineering for Drug Development and Substance Testing) is an education, R&D and networking platform promoting the application of 3D organotypic technologies and microphysiological systems (MPS) for therapy development. TEDD is one of its kind in Europe with the core goal of replacing animal experimentation using 3D technologies. Our community is composed of international Partners from academia, clinics, industry and non-profits. TEDD realises its mission through regular events at the national and international level.

# **Purpose**

The continually rising numbers of compound failures leading to early withdrawals, and the increasing cost of drug development are fuelling the demand for physiologically relevant cell models. Animal testing often fails to predict the effects of drugs on a human. Over the years, 3D organotypic methods including MPS and associated analytical tools became widely accepted and appreciated. Current research demonstrated that 3D in vitro models significantly improved cell-based drug screening and addressed safety and efficacy of substances more efficient than animal models or 2D cell cultures. However, despite the considerable advancement of organotypic technologies and partial adaptation in industry, the full potential is not yet reached. It is important that the companies start adapting and implementing organotypic model systems into their drug development processes. Furthermore, a joint action will help harmonizing and standardizing 3D models and MPS according to assay, scalability and usability enabling direct comparison and assessing their translational value.

# Mission

TEDD's mission is to support the development and application of 3D cell culture technologies and bring these methods to the next level. This includes improving healthy and disease models, developing personalized treatments using organoids, MPS and stem cells to recreate and recapitulate tissue and organ physiology. Furthermore, the validation, harmonisation and segmentation of organotypic methods as well as regulation by the authorities is required. TEDD is aiming at the complete replacement of animal models in research by human in vitro organotypic models and MPS. In order to foster this paradigm shift in biomedical industry, research and the government, we constantly disseminate latest findings and provide education on the state-of-theart 3D technologies. Furthermore, the benefit of these technologies will be further exploited in other industry fields, such as the diagnostics, nutrition and fragrances industry.

# **Activities**

TEDD is actively shaping the 3D cell culture technology landscape. In order to promote knowledge and technology transfer, we organize regular events and activities at national and international level for network collaborators and Partners to ensure exchange and progress including:

- · national and international scientific symposia
- company, university and institute visits
- thematic workshops
- educational courses
- annual meetings
- scientific publications



# **TEDD Partners**

Companies and organisations from various fields and disciplines are welcome to join the TEDD network:

- basic, clinical and applied research institutes
- technology companies
- pharmaceutical, biotechnological and cosmetic industries
- medical product manufacturers
- non-profit organizations and foundations
- clusters

TEDD Partnership Fee

CHF 750.- per year

Application via website www.zhaw.ch/icbt/tedd

# **TEDD Partner Benefits**

Priority access to TEDD events to obtain first-hand information

We initiate and co-organize workshops, seminars, symposia and company visits to keep you up to date with the latest developments in the field of 3D cell culture, MPS and its applications. Flag international conferences are TEDD Annual Meetings, Biointerfaces International, and Dechema 3D Cell Culture Symposium.

Professional networking and high visibility in the community

We bring together national and international business, clinical and academic Partners and provide an interactive platform to exchange information on trends in technology, applications, demands, risks and chances of advanced methodologies.

Long-term support for scientific projects

Partners benefit from integration into larger interdisciplinary projects in collaboration with industry and academia and participate in grant applications initiated and supported by the TEDD network e.g. national research programmes, national thematic networks, European projects, SNF programmes, and applied research projects funded by the Innosuisse.

Communication through periodic reports and newsletter

We publish periodic reports and newsletters, providing TEDD Partners the opportunity to communicate their news and inform about their competences and products.